Peripheral iv
Phase 1Biologic
Peripheral iv is one of 25 biologic programs targeting Hepatitis B. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
252 competitors in Hepatitis B
#DrugCompanyPhaseTrials
1Hydronidone
BBeijing Continent Pharmaceutical Co, Ltd.
Phase 3
Measles Vaccine
GSKPhase 3
F/TDF
GileadPhase 3
Hepatitis B Adjuvanted Vaccine
GSKPhase 3
Vemlidy
GileadPreclinical
Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Quinvaxem
CCrucell Holland BV
Phase 3
Nulojix
Bristol-Myers SquibbPreclinical
HEPCLUDEX
GileadPreclinical
Ziagen
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Peripheral iv. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- SSclnow Biotechnology Co., Ltd.